Exosomal microRNAs as liquid biopsy biomarkers and therapeutic targets in cholangiocarcinoma

Cholangiocarcinoma (CCA) has a poor prognosis due to late diagnosis, diagnostic uncertainty and the lack of sensitivity and specificity of traditional serum markers like CA19-9, which is not sensitive enough to detect CCA at early stages and is insufficient for differentiating CCA from benign biliary disease. Exosomal and extracellular-vesicle (EV) associated microRNAs (miRNAs) are selectively packaged, nuclease protected liquid biopsy candidates that have been reported across multiple biofluids and several have shown discrimination in discovery stage case–control cohorts that compares favourably with CA19-9 within those individual studies; because these comparisons involve different populations, control spectra, analytical platforms and normalization strategies, they do not constitute head-to-head evidence of superiority. RNA therapy approaches that target tumor-suppressive and carcinogenic miRNAs in CCA are being assessed for regulatory affairs and manufacturing feasibility rather than molecular complexity. This review will comprehensively analyse the methodological aspects of current CCA studies, identify the translational implications of non-standardized procedures for exosome isolation, unstandardized normalization methods, and lack of power for single-centre CCA design and compare exosomal miRNAs activity with circulating tumor DNA and known CCA clinical markers. We also discuss integrated precision CCA oncology framework that combines tissue genomics, exosomal miRNAs analysis, and decision-support analytics highlighting the importance of exosomes in the treatment of CCA. Across the studies reviewed, no CCA EV-miRNA candidate has advanced beyond internally validated or retrospectively associated status (evidence Tiers 3–4), and we therefore frame validation priorities alongside, rather than in place of targeted discovery in under-represented CCA subtypes and etiological populations.

Authors

Institutions

Publication Details

Journal
Discover Oncology
Published
2026-11-16
DOI
https://doi.org/10.1007/s12672-026-06138-y
Primary Topic
Extracellular vesicles in disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Exosomal microRNAs as liquid biopsy biomarkers and therapeutic targets in cholangiocarcinoma

Varun Sankar Siva Subramaniam, B. V. Deepika, Duvvuru Prawin Kumar Reddy
2 links
Discover Oncology
Extracellular vesicles in disease
article

Exosomal microRNAs as liquid biopsy biomarkers and therapeutic targets in cholangiocarcinoma

Varun Sankar Siva Subramaniam, B. V. Deepika, Duvvuru Prawin Kumar Reddy
article en

Abstract

Cholangiocarcinoma (CCA) has a poor prognosis due to late diagnosis, diagnostic uncertainty and the lack of sensitivity and specificity of traditional serum markers like CA19-9, which is not sensitive enough to detect CCA at early stages and is insufficient for differentiating CCA from benign biliary disease. Exosomal and extracellular-vesicle (EV) associated microRNAs (miRNAs) are selectively packaged, nuclease protected liquid biopsy candidates that have been reported across multiple biofluids and several have shown discrimination in discovery stage case–control cohorts that compares favourably with CA19-9 within those individual studies; because these comparisons involve different populations, control spectra, analytical platforms and normalization strategies, they do not constitute head-to-head evidence of superiority. RNA therapy approaches that target tumor-suppressive and carcinogenic miRNAs in CCA are being assessed for regulatory affairs and manufacturing feasibility rather than molecular complexity. This review will comprehensively analyse the methodological aspects of current CCA studies, identify the translational implications of non-standardized procedures for exosome isolation, unstandardized normalization methods, and lack of power for single-centre CCA design and compare exosomal miRNAs activity with circulating tumor DNA and known CCA clinical markers. We also discuss integrated precision CCA oncology framework that combines tissue genomics, exosomal miRNAs analysis, and decision-support analytics highlighting the importance of exosomes in the treatment of CCA. Across the studies reviewed, no CCA EV-miRNA candidate has advanced beyond internally validated or retrospectively associated status (evidence Tiers 3–4), and we therefore frame validation priorities alongside, rather than in place of targeted discovery in under-represented CCA subtypes and etiological populations.

Discover Oncology
JSS Academy of Higher Education and Research (IN), JSS College of Pharmacy (IN)
Good health and well-being
Extracellular vesicles in disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon